Randomised trial comparing the introduction of an immediate or deferred new HAART regimen in failing HIV infected patients: the role of lamivudine monotherapy.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 23 Sep 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lamivudine (Primary) ; Abacavir; Antiretrovirals; Atazanavir; Darunavir; Didanosine; Efavirenz; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate; Emtricitabine; Emtricitabine/tenofovir disoproxil fumarate; Enfuvirtide; Fosamprenavir; Lamivudine/abacavir; Lamivudine/zidovudine; Lopinavir/ritonavir; Maraviroc; Nevirapine; Raltegravir; Ritonavir; Saquinavir; Stavudine; Tenofovir disoproxil fumarate; Tipranavir; Zidovudine
Indications HIV infections
Focus Therapeutic Use
Acronyms MONO

22 Sep 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
08 Jun 2011 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com